Dolasetron

Structural formula
General
Non-proprietary name	Dolasetron
other names	(3 R ) -10-Oxo-8-azatricyclo [5.3.1.0 3,8 ] undec-5-yl-1 H -indole-3-carboxylate ( IUPAC )
Molecular formula	C 19 H 20 N 2 O 3
Brief description	white powder (mesylate hydrate)
External identifiers / databases
EC number	601-402-4
ECHA InfoCard	100.130.141
PubChem	60654
ChemSpider	30845229
DrugBank	DB00757
Wikidata	Q1829318
Drug information
ATC code	A04 AA04
Drug class	5-HT3 antagonist
properties
Molar mass	324.37 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Mesylate	no GHS pictograms
	no GHS pictograms
H and P phrases	H: no H-phrases
	P: no P-phrases
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dolasetron is a 5-HT3 antagonist used to treat nausea and vomiting in chemotherapy and PONV . Dolasetron is administered in a dosage of 50 to 200 milligrams. The half-life is 7 to 9 hours. Another area of application of Dolasetron is veterinary medicine , where it is also used against vomiting.

Side effects

Its most common side effects are: severe allergic reactions, fast or pounding heartbeats, fainting or fainting , slow heartbeats, weak pulse, slow breathing, chest pain, prolongation of the QT / QTc interval , pain in the arm or leg, nausea, sweating , general mood, headache, tiredness.

Trade names

Dolasetron came onto the German market in 1997 under the trade name Anemet . Approvals for all dosage forms were given up by the manufacturer in 2011 after cardiac arrhythmias occurred as a side effect of intravenous administration .

Individual evidence

↑ ^a ^b Data sheet Dolasetron mesylate hydrate, ≥98% (HPLC), powder from Sigma-Aldrich , accessed on January 25, 2013 ( PDF ).
↑ Josef Donnerer: Antiemetic Therapy. ISBN 3-8055-7547-5 .
↑ Anzemet Injection (Dolasetron) - Description and Clinical Pharmacology. In: DrugLib.com. 2012, accessed January 22, 2013 .
↑ Harald Schmidt: Pharmacology and Toxicology. ISBN 3-7945-2295-8 .
↑ Reto Neiger: Differential Diagnoses of Internal Medicine in Dogs and Cats: From Key Symptom to Diagnosis . Georg Thieme Verlag, 2009, ISBN 978-3-8304-1119-2 .
↑ Anzemet Tablets (Dolasetron) Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information at RxList. RxList Inc., June 10, 2011, accessed January 22, 2013 .
↑ Side effects of Dolasetron - for the consumer. In: Side Effects.co. 2013, archived from the original on March 4, 2016 ; Retrieved January 22, 2013 .
↑ Information letter for medical professionals on Anemet 200 mg tablets. (PDF; 138 kB) Sanofi-Aventis Deutschland GmbH, April 2001, accessed on January 22, 2013 .

[Sigma-1] Data sheet Dolasetron mesylate hydrate, ≥98% (HPLC), powder from Sigma-Aldrich , accessed on January 25, 2013 ( PDF ).

[2] Josef Donnerer: Antiemetic Therapy. ISBN 3-8055-7547-5 .

[3] Anzemet Injection (Dolasetron) - Description and Clinical Pharmacology. In: DrugLib.com. 2012, accessed January 22, 2013 .

[4] Harald Schmidt: Pharmacology and Toxicology. ISBN 3-7945-2295-8 .

[5] Reto Neiger: Differential Diagnoses of Internal Medicine in Dogs and Cats: From Key Symptom to Diagnosis . Georg Thieme Verlag, 2009, ISBN 978-3-8304-1119-2 .

[6] Anzemet Tablets (Dolasetron) Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information at RxList. RxList Inc., June 10, 2011, accessed January 22, 2013 .

[7] Side effects of Dolasetron - for the consumer. In: Side Effects.co. 2013, archived from the original on March 4, 2016 ; Retrieved January 22, 2013 .

[8] Information letter for medical professionals on Anemet 200 mg tablets. (PDF; 138 kB) Sanofi-Aventis Deutschland GmbH, April 2001, accessed on January 22, 2013 .